New pill combo aims to tame hepatitis d in small trial

NCT ID NCT05229991

Completed Disease control Sponsor: Soroka University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested a once-daily combination of two drugs, lonafarnib and ritonavir, in 10 adults with chronic hepatitis D. The goal was to see if the regimen is safe and can lower the amount of virus in the blood over 48 weeks of treatment and 24 weeks of follow-up. Because the study is very small, the results are preliminary and need confirmation in larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lonafarnib and ritonavir
What this could lead to: If it works, this could offer a simpler once-daily pill regimen to control hepatitis D virus levels in patients with chronic infection.
What could go wrong: This is a very small, early-phase trial with only 10 participants, so results may not apply broadly. The drug combination may not effectively lower the virus or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS D, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection hepatitis D virus infection Hepatitis D, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS D, CHRONIC

Contacts and locations

Locations

Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey

Istanbul, Turkey (Türkiye)
New Zealand Liver Transplant Unit, Auckland City Hospital

Auckland, New Zealand
Soroka UMC

Beersheba, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.